View Filing Data

Cash and cash equivalents

$ 66,479

CURRENT ASSETS:

240,923

$ 445,082

^[1]

Accounts receivable, net of allowance for doubtful accounts of $1,121 at September 30, 2016 and $1,101 at December 31, 2015

124,934

56,161

^[1]

Inventories

401,312

49,264

^[1]

Prepaid income taxes

13,398

11,235

^[1]

Prepaid expenses and other current assets

121,358

7,355

^[1]

Assets held-for-sale

2,508

^[1]

Total current assets

904,433

569,097

^[1]

PROPERTY AND EQUIPMENT, net

374,590

85,696

^[1]

GOODWILL

6,652

5,577

^[1]

INTANGIBLE ASSETS, net

160,346

22,383

^[1]

DEFERRED INCOME TAXES

11,597

21,935

^[1]

Other Assets, Noncurrent

29,679

^[1]

TOTAL ASSETS

1,487,297

704,688

^[1]

CURRENT LIABILITIES:

Accounts payable

40,443

14,641

^[1]

Accrued Income Taxes, Current

146,317

25,896

^[1]

2,333

^[1]

Total current liabilities

189,093

40,537

^[1]

LONG-TERM LIABILITIES

70,939

1,107

^[1]

DEFERRED INCOME TAXES

4,428

1,370

^[1]

Accrued Income Taxes, Noncurrent

1,519

COMMITMENTS AND CONTINGENCIES

^[1]

Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value

25,000

LONG-TERM OBLIGATIONS

75,000

^[1]

STOCKHOLDERS' EQUITY:

Convertible preferred stock, $1.00 par value Authorized-500 shares; Issued and outstanding - none

^[1]

Common stock, $0.10 par value - Authorized-80,000 shares; Issued and Outstanding 16,307 shares at September 30, 2016 and 16,086 shares at December 31, 2015

1,984

1,633

^[1]

Additional paid-in capital

592,953

162,828

^[1]

Treasury Stock, at cost - 0 shares at September 30, 2016 and 0 shares at December 31, 2015

(15)

(14)

^[1]

Retained earnings

535,783

516,980

^[1]

Accumulated other comprehensive loss

(9,387)

(21,272)

^[1]

Total stockholders' equity

1,121,318

660,155

^[1]

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY

1,487,297

704,688

^[1]

Allowance for doubtful accounts

$ 3,042

$ 1,073

Convertible preferred stock, par value

$ 1.00

Convertible preferred stock, authorized shares

500,000

Convertible preferred stock, issued shares

Convertible preferred stock, outstanding shares

Common stock, par value

$ 0.10

Common stock, shares authorized

80,000,000

Common stock, shares issued

19,844,000

16,338,000

Common stock, shares outstanding

19,844,000

16,338,000

Treasury Stock, Shares

(90)

(93)

[1]	December 31, 2016 balances were derived from audited consolidated financial statements.

Condensed Consolidated Statements of Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
REVENUES:
Net sales	$ 331,218	$ 96,712	$ 578,461	$ 186,561
Other Revenue, Net	296	9	792	15
TOTAL REVENUE	331,514	96,721	579,253	186,576
COST OF GOODS SOLD	243,452	46,589	402,246	87,211
GROSS PROFIT	88,062	50,132	177,007	99,365
OPERATING EXPENSES:
Selling, general and administrative	85,106	22,491	149,992	44,466
Research and development	12,967	3,338	24,608	6,651
Restructuring and strategic transaction	19,921	1,533	49,322	1,533
Change in fair value of earn-out	6,000	0	6,000	0
TOTAL OPERATING EXPENSES	123,994	27,362	229,922	52,650
(LOSS) INCOME FROM OPERATIONS	(35,932)	22,770	(52,915)	46,715
Bargain purchase gain	0	1,110	63,237	1,110
Interest Expense	(525)	(48)	(1,038)	(77)
OTHER (EXPENSE) INCOME, net	(2,720)	125	(2,613)	301
(LOSS) INCOME BEFORE INCOME TAXES	(39,177)	23,957	6,671	48,049
BENEFIT (PROVISION) FOR INCOME TAXES	2,117	(7,351)	12,132	(13,283)
NET (LOSS) INCOME	$ (37,060)	$ 16,606	$ 18,803	$ 34,766
NET (LOSS) INCOME PER SHARE
Basic (in dollars per share)	$ (1.87)	$ 1.03	$ 0.98	$ 2.16
Diluted (in dollars per share)	$ (1.87)	$ 0.98	$ 0.93	$ 2.05
WEIGHTED AVERAGE NUMBER OF SHARES
Basic (in shares)	19,821	16,091	19,153	16,070
Diluted (in shares)	19,821	17,000	20,312	16,964

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Net income	$ (37,060)	$ 16,606	$ 18,803	$ 34,766
Other comprehensive (loss) income, net of tax
Cash flow hedge adjustments, net of taxes of $(685) for each of the three and six months ended June 30, 2017	1,119	0	1,119	0
Foreign currency translation adjustment, net of taxes of $8 and $(746) for the three months ended June 30, 2017 and 2016, respectively, and $56 and $413 for the six months ended June 30, 2017 and 2016, respectively	8,888	(2,267)	10,914	1,832
Other Adjustments, Net of Taxes of $0 for all periods	(151)	0	(148)	0
Other comprehensive income (loss), net of taxes	9,856	(2,267)	11,885	1,832
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	(27,204)	14,339	30,688	36,598
Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax	(685)	0	(685)	0
Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax	8	(746)	56	(413)
Other Comprehensive (Income) Loss, Other Adjustments, Tax	$ 0	$ 0	$ 0	$ 0

Condensed Consolidated Statements of Cash Flows
$ in Thousands

6 Months Ended

Jun. 30, 2017

USD ($)

Jun. 30, 2016

USD ($)

CASH FLOWS FROM OPERATING ACTIVITIES:

Net income

$ 18,803

$ 34,766

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation and amortization

29,906

9,648

Provision for doubtful accounts

1,925

Provision for warranty and returns

2,031

(125)

Stock compensation

8,805

7,674

Loss (gain) on disposal of property and equipment

3,010

Bond premium amortization

121

Bargain purchase gain

(63,237)

(1,110)

Change in fair value of earn-out

6,000

Other Noncash Expense

1,804

Cash provided by (used in) changes in operating assets and liabilities

Accounts receivable

(70,606)

(2,527)

Inventories

66,870

(5,479)

Prepaid expenses and other assets

(95,254)

(3,784)

Accounts payable

8,785

3,752

Income taxes, including excess tax benefits and deferred income taxes

66,479

(5,985)

(14,185)

4,793

Net cash provided by operating activities

(28,864)

41,775

CASH FLOWS FROM INVESTING ACTIVITIES:

Purchases of property and equipment

(27,199)

(9,112)

Proceeds from sale of asset

Payments to Acquire Businesses, Net of Cash Acquired

157,097

2,606

Intangible assets additions

(2,005)

(513)

Purchases of investment securities

(18,106)

Proceeds from sale of investment securities

31,765

Net cash (used in) provided by investing activities

(186,299)

1,429

CASH FLOWS FROM FINANCING ACTIVITIES:

Proceeds from exercise of stock options

10,944

7,796

Proceeds from employee stock purchase plan

1,326

1,197

Purchase of treasury stock

(3,739)

(16,911)

Net cash provided by financing activities

8,531

(7,918)

Effect of exchange rate changes on cash

2,473

1,445

NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS

(204,159)

36,731

CASH AND CASH EQUIVALENTS, beginning of period

445,082

^[1]

336,164

CASH AND CASH EQUIVALENTS, end of period

240,923

372,895

NON-CASH INVESTING ACTIVITIES

Capital Expenditures Incurred but Not yet Paid

6,024

1,574

Fair Value of Assets Acquired

881,732

3,572

Payments to Acquire Businesses, Net of Cash Acquired

(157,097)

(2,606)

Proceeds from Issuance of Debt

(75,000)

Estimated working capital adjustment

7,512

Business Combination, Contingent Consideration, Liability, Noncurrent

(19,000)

Business Combination, Consideration Transferred, Equity Issued, Fair Value

(413,139)

BARGAIN PURCHASE GAIN

(63,237)

(1,110)

Goodwill, Acquired During Period

1,015

Goodwill, Period Increase (Decrease)

(218)

Liabilities Assumed

$ 162,786

Increase (Decrease) in Assumed Liabilities

$ (362)

[1]	December 31, 2016 balances were derived from audited consolidated financial statements.

Basis of Presentation:	6 Months Ended
Basis of Presentation:	Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation [Text Block]	Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S.") and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and reflect all adjustments, consisting of only normal recurring adjustments, which are, in the opinion of management, necessary for a fair statement of the consolidated results for the interim periods presented. Results for the interim period are not necessarily indicative of results for the full year. Certain information and footnote disclosures normally included in annual consolidated financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. The condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Annual Report on Form 10-K of ICU Medical, Inc., ("ICU") a Delaware corporation, filed with the SEC for the year ended December 31, 2016. We are engaged in the development, manufacturing and sale of innovative medical devices used in infusion therapy, and critical care markets. We sell the majority of our products through our direct sales force and through independent distributors throughout the U. S. and internationally. Additionally, we sell our products on an original equipment manufacturer basis to other medical device manufacturers. All subsidiaries are wholly owned and are included in the condensed consolidated financial statements. All intercompany balances and transactions have been eliminated. Certain prior year amounts have been reclassified to conform to the current period’s presentation. These reclassifications had no impact on previously reported results of operations.

New Accounting Pronouncements:	6 Months Ended
New Accounting Pronouncements:	Jun. 30, 2017
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
New Accounting Pronouncements and Changes in Accounting Principles [Text Block]	New Accounting Pronouncements Recently Adopted Accounting Standards In July 2015, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") No. 2015-11 Inventory (Topic 330): Simplifying the Measurement of Inventory. ASU 2015-11 changes the measurement of inventory within the scope of the ASU (e.g. FIFO or average cost) from lower of cost or market to lower of cost and net realizable value ("NRV"). NRV is defined as estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Prior to the ASU, U.S. generally accepted accounting principles required an entity to measure inventory at the lower of cost or market. Market is measured using replacement cost unless it is above NRV (commonly referred to as “ceiling”) or below NRV less an approximately normal profit margin (commonly referred to as “floor”). For inventory within its scope, the ASU eliminates the notions of replacement cost and NRV less a normal profit margin, which is intended to simplify the accounting for inventory. The amendments are effective prospectively for the fiscal years, and interim reporting periods within those years, beginning on or after December 15, 2016. We adopted this ASU on January 1, 2017. This ASU did not have a material impact on our condensed consolidated financial statements. Recently Issued Accounting Standards In May 2017, the FASB issued ASU No. 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting. The amendments in this update provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. Under the ASU, an entity will account for the effects of a modification unless (i) the fair value of the modified award is the same as the fair value of the original award immediately before the original award is modified, (ii) the vesting conditions of the modified award are the same vesting conditions as the original award immediately before the original award is modified, and (iii) the classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. The amendments in this ASU are effective prospectively for annual periods, and interim periods within those annual periods, beginning December 15, 2017. This ASU is not expected to have a material impact on our condensed consolidated financial statements or related footnote disclosures. In January 2017, the FASB issued ASU No. 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment. The amendments in this update remove the second step of the impairment test. An entity will apply a one-step quantitative test and record the amount of goodwill impairment as the excess of a reporting unit's carrying amount over its fair value, not to exceed the total amount of goodwill allocated to the reporting unit. The new guidance does not amend the optional qualitative assessment of goodwill impairment. The amendments in ASU 2017-04 are effective for the annual or interim impairment test in fiscal years beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. This ASU is not expected to have a material impact on our condensed consolidated financial statements or related footnote disclosures. In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business. The amendments in this update clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The amendments in this update provide a screen to determine when a set (integrated set of assets and activities) is not a business. If the screen is not met, it (1) requires that to be considered a business, a set must include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create output and (2) removes the evaluation of whether a market participant could replace the missing elements. The amendments in ASU 2017-01 are effective for annual periods and interim periods within those annual periods beginning after December 15, 2017. The amendments in this ASU should be applied prospectively on or after the effective date. This ASU is not expected to have a material impact on our condensed consolidated financial statements or related disclosures. In October 2016, the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory. Current generally accepted accounting principles prohibits the recognition of current and deferred income taxes for an intra-entity asset transfer until after the asset has been sold to an outside party. The amendments in ASU 2016-16 eliminates this prohibition, accordingly an entity should recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. Amendments in this update are effective for annual reporting periods beginning after December 15, 2017. Early adoption is permitted in the first interim period of an annual reporting period. The amendments should be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. We are currently evaluating the impact of this ASU on the consolidated financial statements and related disclosures. In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 provides specific guidance on eight cash flow issues where current guidance is unclear or does not include any specifics on classification. The eight specific cash flow issues are: debt prepayment or debt extinguishment costs; settlement of zero-coupon debt instruments or other debt instruments with zero coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing; contingent consideration payments made after a business combination; proceeds from the settlement of insurance claims; proceeds from the settlement of corporate-owned life insurance policies, including bank-owned policies; distributions received from equity method investees; beneficial interests in securitization transactions; and separately identifiable cash flows and application of the predominance principle. The amendments in ASU 2016-15 are effective for annual periods and interim periods within those annual periods beginning after December 15, 2017. Early adoption is permitted. If adopted in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes the interim period. Amendments should be applied using a retrospective transition method to each period presented. We are currently evaluating the impact of this ASU on the consolidated financial statements and related disclosures. In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. This update amends the FASB's guidance on the impairment of financial instruments by requiring timelier recording of credit losses on loans and other financial instruments. The ASU adds an impairment model that is based on expected losses rather than incurred losses. The ASU also amends the accounting for credit losses on available-for-sale debt securities and purchased financial assets with credit deterioration. The amendments in this update will be effective for fiscal years beginning after December 15, 2019. Early adoption is permitted as of the fiscal years beginning after December 15, 2018. The updated guidance requires a modified retrospective adoption. We are currently evaluating the impact of this ASU on the consolidated financial statements and related disclosures. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The amendments in this update require an entity to recognize a right-of-use asset and lease liability for all leases with terms of more than 12 months. Recognition, measurement and presentation of expenses will depend on classification as finance or operating lease. The amendments also require certain quantitative and qualitative disclosures about leasing arrangements. The amendments in this update will be effective for fiscal years beginning after December 15, 2019. Early adoption is permitted. The updated guidance requires a modified retrospective adoption. We are currently evaluating the impact of this ASU on the consolidated financial statements and related disclosures. In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities, which amends certain aspects of recognition, measurement, presentation and disclosure of financial instruments. This amendment requires all equity investments to be measured at fair value with changes in the fair value recognized through net income (other than those accounted for under the equity method of accounting or those that result in the consolidation of the investee). The amendments in this update will be effective for fiscal years beginning after December 15, 2017. Early adoption of the amendments is not permitted with the exception of the provision requiring the recognition in other comprehensive income the fair value change from instrument-specific credit risk measured using the fair value option for financial instruments. We are currently evaluating the impact of this ASU on the consolidated financial statements and related disclosures. In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 removes inconsistencies and weaknesses in revenue requirements, provides a more robust framework for addressing revenue issues, improves comparability of revenue recognition practices across entities, industries, jurisdictions and capital markets, provides more useful information to users of financial statements through improved disclosure requirements and simplifies the preparation of financial statements by reducing the number of requirements to which an entity must refer. This guidance requires that an entity depict the consideration by applying a five-step analysis in determining when and how revenue is recognized. The new model will require revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration a company expects to receive in exchange for those goods or services. On April 1, 2015, the FASB voted for a one-year deferral of the effective date of the new revenue recognition standard, ASU 2014-09. On July 15, 2015, the FASB affirmed these changes, which requires public entities to apply the amendments in ASU 2014-09 for annual reporting beginning after December 15, 2017. Early adoption is permitted beginning after December 31, 2016, the original effective date in ASU 2014-09. Subsequent to the issuance of this ASU, the FASB issued three amendments: ASU No. 2016-08 which clarifies principal versus agent considerations; ASU 2016-10 which clarifies guidance related to identifying performance obligations and licensing implementation; and ASU 2016-12 which provides narrow-scope improvements and practical expedients. All of the amendments have the same effective dates mentioned above. We previously disclosed that we did not anticipate a material impact on our consolidated financial statements from adoption of any of the above. In light of the Hospira Infusion Systems ("HIS") acquisition we are reevaluating the impact of this ASU on our consolidated financial statements. We expect to have enhanced disclosures upon adoption of this ASU. We now expect to adopt the modified restrospective method when adopting this ASU.
Description of New Accounting Pronouncements Not yet Adopted [Text Block]	Recently Issued Accounting Standards In May 2017, the FASB issued ASU No. 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting. The amendments in this update provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. Under the ASU, an entity will account for the effects of a modification unless (i) the fair value of the modified award is the same as the fair value of the original award immediately before the original award is modified, (ii) the vesting conditions of the modified award are the same vesting conditions as the original award immediately before the original award is modified, and (iii) the classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. The amendments in this ASU are effective prospectively for annual periods, and interim periods within those annual periods, beginning December 15, 2017. This ASU is not expected to have a material impact on our condensed consolidated financial statements or related footnote disclosures. In January 2017, the FASB issued ASU No. 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment. The amendments in this update remove the second step of the impairment test. An entity will apply a one-step quantitative test and record the amount of goodwill impairment as the excess of a reporting unit's carrying amount over its fair value, not to exceed the total amount of goodwill allocated to the reporting unit. The new guidance does not amend the optional qualitative assessment of goodwill impairment. The amendments in ASU 2017-04 are effective for the annual or interim impairment test in fiscal years beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. This ASU is not expected to have a material impact on our condensed consolidated financial statements or related footnote disclosures. In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business. The amendments in this update clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The amendments in this update provide a screen to determine when a set (integrated set of assets and activities) is not a business. If the screen is not met, it (1) requires that to be considered a business, a set must include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create output and (2) removes the evaluation of whether a market participant could replace the missing elements. The amendments in ASU 2017-01 are effective for annual periods and interim periods within those annual periods beginning after December 15, 2017. The amendments in this ASU should be applied prospectively on or after the effective date. This ASU is not expected to have a material impact on our condensed consolidated financial statements or related disclosures. In October 2016, the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory. Current generally accepted accounting principles prohibits the recognition of current and deferred income taxes for an intra-entity asset transfer until after the asset has been sold to an outside party. The amendments in ASU 2016-16 eliminates this prohibition, accordingly an entity should recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. Amendments in this update are effective for annual reporting periods beginning after December 15, 2017. Early adoption is permitted in the first interim period of an annual reporting period. The amendments should be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. We are currently evaluating the impact of this ASU on the consolidated financial statements and related disclosures. In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 provides specific guidance on eight cash flow issues where current guidance is unclear or does not include any specifics on classification. The eight specific cash flow issues are: debt prepayment or debt extinguishment costs; settlement of zero-coupon debt instruments or other debt instruments with zero coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing; contingent consideration payments made after a business combination; proceeds from the settlement of insurance claims; proceeds from the settlement of corporate-owned life insurance policies, including bank-owned policies; distributions received from equity method investees; beneficial interests in securitization transactions; and separately identifiable cash flows and application of the predominance principle. The amendments in ASU 2016-15 are effective for annual periods and interim periods within those annual periods beginning after December 15, 2017. Early adoption is permitted. If adopted in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes the interim period. Amendments should be applied using a retrospective transition method to each period presented. We are currently evaluating the impact of this ASU on the consolidated financial statements and related disclosures. In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. This update amends the FASB's guidance on the impairment of financial instruments by requiring timelier recording of credit losses on loans and other financial instruments. The ASU adds an impairment model that is based on expected losses rather than incurred losses. The ASU also amends the accounting for credit losses on available-for-sale debt securities and purchased financial assets with credit deterioration. The amendments in this update will be effective for fiscal years beginning after December 15, 2019. Early adoption is permitted as of the fiscal years beginning after December 15, 2018. The updated guidance requires a modified retrospective adoption. We are currently evaluating the impact of this ASU on the consolidated financial statements and related disclosures. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The amendments in this update require an entity to recognize a right-of-use asset and lease liability for all leases with terms of more than 12 months. Recognition, measurement and presentation of expenses will depend on classification as finance or operating lease. The amendments also require certain quantitative and qualitative disclosures about leasing arrangements. The amendments in this update will be effective for fiscal years beginning after December 15, 2019. Early adoption is permitted. The updated guidance requires a modified retrospective adoption. We are currently evaluating the impact of this ASU on the consolidated financial statements and related disclosures. In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities, which amends certain aspects of recognition, measurement, presentation and disclosure of financial instruments. This amendment requires all equity investments to be measured at fair value with changes in the fair value recognized through net income (other than those accounted for under the equity method of accounting or those that result in the consolidation of the investee). The amendments in this update will be effective for fiscal years beginning after December 15, 2017. Early adoption of the amendments is not permitted with the exception of the provision requiring the recognition in other comprehensive income the fair value change from instrument-specific credit risk measured using the fair value option for financial instruments. We are currently evaluating the impact of this ASU on the consolidated financial statements and related disclosures. In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 removes inconsistencies and weaknesses in revenue requirements, provides a more robust framework for addressing revenue issues, improves comparability of revenue recognition practices across entities, industries, jurisdictions and capital markets, provides more useful information to users of financial statements through improved disclosure requirements and simplifies the preparation of financial statements by reducing the number of requirements to which an entity must refer. This guidance requires that an entity depict the consideration by applying a five-step analysis in determining when and how revenue is recognized. The new model will require revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration a company expects to receive in exchange for those goods or services. On April 1, 2015, the FASB voted for a one-year deferral of the effective date of the new revenue recognition standard, ASU 2014-09. On July 15, 2015, the FASB affirmed these changes, which requires public entities to apply the amendments in ASU 2014-09 for annual reporting beginning after December 15, 2017. Early adoption is permitted beginning after December 31, 2016, the original effective date in ASU 2014-09. Subsequent to the issuance of this ASU, the FASB issued three amendments: ASU No. 2016-08 which clarifies principal versus agent considerations; ASU 2016-10 which clarifies guidance related to identifying performance obligations and licensing implementation; and ASU 2016-12 which provides narrow-scope improvements and practical expedients. All of the amendments have the same effective dates mentioned above. We previously disclosed that we did not anticipate a material impact on our consolidated financial statements from adoption of any of the above. In light of the Hospira Infusion Systems ("HIS") acquisition we are reevaluating the impact of this ASU on our consolidated financial statements. We expect to have enhanced disclosures upon adoption of this ASU. We now expect to adopt the modified restrospective method when adopting this ASU.

The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6507316

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Direct Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=66092750

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22583-107794

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Indirect Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6515603

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22580-107794

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.10-01.(b)(6))
-URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Accounting Change
-URI http://asc.fasb.org/extlink&oid=6503790

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22499-107794

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Retrospective Application
-URI http://asc.fasb.org/extlink&oid=6523989

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=68064558&loc=d3e765-108305

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68064558&loc=d3e725-108305

Business Combination Disclosure [Text Block]

Acquisition and Strategic Transaction (Notes)

6 Months Ended

Jun. 30, 2017

Business Combinations [Abstract]

Acquisitions and Strategic Transaction Expenses

Acquisitions

On February 1, 2017, we acquired 100% interest in Fannin (UK) Limited ("Fannin") for total consideration of approximately $1.5 million. Fannin provides infusion therapy consumable products to the healthcare sector in the United Kingdom and Ireland.

On February 3, 2017, we acquired 100% interest in Pfizer Inc.’s (“Pfizer”) HIS business for total cash consideration of approximately $260.0 million (net of estimated working capital adjustments paid at closing), which was financed with existing cash balances and a $75 million three-year interest-only seller note. We also issued 3.2 million shares of our common stock. The fair value of the common shares issued to Pfizer was determined based on the closing price of our common shares on the issuance date, discounted to reflect a contractual lock-up period whereby Pfizer cannot transfer the shares, subject to certain exceptions, until the earlier of (i) the expiration of Pfizer’s services to us in the related transitional services agreement or (ii) eighteen months from the closing date. Additionally, Pfizer also may be entitled up to an additional $225 million in cash contingent consideration based on the achievement of performance targets for the combined company for the three years ending December 31, 2019 ("Earnout Period"). In the event that the sum of our Adjusted EBITDA as defined in the Amended and Restated Stock and Asset Purchase Agreement between us and Pfizer (the “HIS Purchase Agreement”) for the three years in the Earnout Period (the "Cumulative Adjusted EBITDA") is equal to or exceeds approximately $1 billion ("the "Earnout Target"), then Pfizer will be entitled to receive the full amount of the earnout. In the event that the Cumulative Adjusted EBITDA is equal to or greater than 85% of the Earnout Target (but less than the Earnout Target), Pfizer will be entitled to receive the corresponding percentage of the earnout. In the event that the Cumulative Adjusted EBITDA is less than 85% of the Earnout Target, then no earnout amount will be earned by Pfizer. The initial fair value of the earn-out was determined by employing a Monte Carlo simulation in a risk neutral framework. The underlying simulated variable was adjusted EBITDA. The adjusted EBITDA volatility estimate was based on a study of historical asset volatility for a set of comparable public companies. The model includes other assumptions including the market price of risk, which was calculated as the weighted average cost of capital ("WACC") less the long term risk free rate. We believe that the acquisition of the HIS business, which includes IV pumps, solutions and consumable devices complements our pre-existing business by creating a company that has a complete infusion therapy product portfolio. We believe that the acquisition significantly enhances our global footprint and platform for continued competitiveness and growth.

With the acquisition of HIS, pre-existing long-term supply and distribution contracts between ICU and HIS were effectively terminated.

Deferred Closings

In the HIS Purchase Agreement, we agreed with Pfizer to defer the local closing of the HIS business in certain foreign jurisdictions (the “Deferred Closing Businesses”) for periods ranging by jurisdiction from 3 to 12 months after the February 3, 2017 closing date (the "Deferred Closing Period"). The net assets in these jurisdictions represent an immaterial portion of the total HIS business net assets.

At the February 3, 2017 HIS business transaction closing, we entered into a Net Economic Benefit Agreement with Pfizer under which we agreed that (i) during the Deferred Closing Period, the economic benefits and burdens of the Deferred Closing Businesses are for our account, and we are to be treated as the beneficial owner of the Deferred Closing Businesses and (ii) Pfizer would continue to operate the Deferred Closing Businesses under our direction.

Preliminary Purchase Price

The following table summarizes the preliminary purchase price, subject to working capital adjustments, and the preliminary allocation of the purchase price related to the assets and liabilities purchased (in thousands):



Estimated cash consideration for acquired assets	$	177,527
Fair value of Seller Note	75,000
Preliminary fair value of contingent consideration payable to Pfizer (long-term)	19,000

Issuance of ICU Medical, Inc. common shares:
Number of shares issued to Pfizer	3,200
Price per share (ICU's trading closing share price on the Closing Date)	$	140.75
Fair value of ICU shares issued to Pfizer	$	450,400
Less: Preliminary discount due to lack of marketability of 8.3%	(37,261		)
Equity portion of purchase price	413,139
Total estimated consideration to be paid	$	684,666

Preliminary Purchase Price Allocation:
Cash and cash equivalents	$	29,475
Trade receivables	362
Inventories	417,317
Prepaid expenses and other assets	4,766
Property and equipment	288,486
Intangible assets⁽¹⁾	139,000
Other assets	31,283
Accounts payable	(12,381		)
Accrued liabilities	(54,794		)
Long-term liabilities⁽²⁾	(68,510		)
Total identifiable net assets acquired	$	775,004
Deferred tax liability	(27,101		)
Estimated Gain on Bargain Purchase	(63,237		)
Estimated Purchase Consideration	$	684,666

______________________________

⁽¹⁾ Preliminary identifiable intangible assets includes $56 million of customer relationships, $44 million of developed technology - pumps and dedicated sets, $34 million of developed technology - consumables, and $5 million of in-process research and development ("IPR&D"). The weighted amortization period for the total identifiable assets is approximately nine years, for customer relationships the weighted amortization period is eight years, for the developed technology - pumps and dedicated sets the weighted amortization period is ten years and for the developed technology - consumables the weighted amortization period is twelve years. The IPR&D has an indefinite life until the associated research and development efforts are complete.

⁽²⁾Preliminary long-term liabilities primarily consisted of contract liabilities, product liabilities and long-term employee benefits.

The fair value of the assets acquired and liabilities assumed exceeded the fair value of the consideration to be paid resulting in a bargain purchase gain. Before recognizing a gain on a bargain purchase, we reassessed the methods used in the purchase accounting and verified that we had identified all of the assets acquired and all of the liabilities assumed, and that there were no additional assets or liabilities to be considered. We also reevaluated the fair value of the contingent consideration transferred to determine that it was appropriate. We determined that the bargain purchase gain was primarily attributable to potential future restructuring made necessary due to the current level of sales demand which did not qualify to be recorded as a liability in the application of acquisition accounting. Restructuring costs, if incurred, would be expensed in future periods. The bargain purchase gain is separately stated below income from operations in the accompanying condensed consolidated statements of operations for the three and six months ended June 30, 2017.

The above purchase price and purchase price allocation are preliminary and subject to future revision as the acquired assets and liabilities assumed are dependent upon the finalization of the related valuations.

The identifiable intangible assets and other long-lived assets acquired have been valued as Level 3 assets at fair market value. The estimated fair value of identifiable intangible assets were developed using the income approach and are based on critical estimates, judgments and assumptions derived from: analysis of market conditions; discount rate; discounted cash flows; royalty rates; customer retention rates; and estimated useful lives. Fixed assets were valued with the consideration of remaining economic lives. The raw materials inventory was valued at historical cost and adjusted for any obsolescence, the work in process was valued at estimated sales proceeds less costs to complete and costs to sell, and finished goods inventory was valued at estimated sales proceeds less costs to sell. The prepaid expenses and other current assets and assumed liabilities were recorded at their carrying values as of the date of the acquisition, as their carrying values approximated their fair values due to their short-term nature.

We did not disclose the proforma revenue and earnings information required by ASC 805, Business Combinations as preparation of the information was not practicable. The HIS business is a carve-out of Pfizer's business and the standalone data for the prior year reporting period was not available.

Strategic Transaction and Integration Expenses

We incurred and expensed $12.4 million and $33.5 million in transaction and integration costs during the three and six months ended June 30, 2017, respectively primarily related to our acquisition of the HIS business. We incurred $1.1 million in transaction costs during the three and six months ended June 30, 2016 related to the 2015 acquisition of EXC Holding Corp. and to our 2016 acquisition of Tangent Medical Technologies, Inc.

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1524-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4922-128472

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4934-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4926-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=73530397&loc=SL65897772-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

Restructuring and Related Activities Disclosure [Text Block]

Restructuring Charges (Notes)

6 Months Ended

Jun. 30, 2017

Restructuring Charges [Abstract]

Restructuring Charges

During the six months ended June 30, 2017, we incurred restructuring charges related to the acquisition of the HIS business (see Note 3: Acquisitions and Strategic Transaction Expenses). The restructuring charges were incurred as a result of integrating the acquired operations into our business and include severance costs related to involuntary employee terminations and facility exit costs related to the closure of the Dominican Republic manufacturing facilities acquired from Pfizer. We expect to complete these restructuring activities by the end of 2017. All material charges in regard to these restructuring activities have been incurred as of June 30, 2017.

During the year ended December 31, 2015, we incurred restructuring charges related to an agreement with Dr. Lopez, a member of our Board of Directors and a former employee in our research and development department, pursuant to which we bought out Dr. Lopez's right to employment under his then-existing employment agreement. The buy-out, including payroll taxes, is paid in equal monthly installments until December 2020.

The following table summarizes the details of changes in our restructuring-related accrual for the period ending June 30, 2017 (in thousands):



	Accrued Balance December 31, 2016		Charges Incurred		Payments			Other Adjustments			Accrued Balance June 30, 2017
Severance pay and benefits	$	53	$	11,807	$	(7,313	)	$	(17	)	$	4,530
Employment agreement buyout	1,477		—		(183		)	—			1,294
Facility closure expenses	—		4,019		(2,067		)	(1,952		)	—
	$	1,530	$	15,826	$	(9,563	)	$	(1,969	)	$	5,824

Net Income Per Share:

6 Months Ended

Jun. 30, 2017

Earnings Per Share [Abstract]

Net Income Per Share [Text Block]

Net Income Per Share

Basic earnings per share is computed by dividing net income by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing net income by the weighted-average number of common shares outstanding during the period plus dilutive securities. Dilutive securities include outstanding common stock options and unvested restricted stock units, less the number of shares that could have been purchased with the proceeds from the exercise of the options, using the treasury stock method. Options that are anti-dilutive, where their exercise price exceeds the average market price of the common stock are not included in the treasury stock method calculation. There were no and 61 anti-dilutive securities for the three and six months ended June 30, 2017, respectively. There were no and 4,300 anti-dilutive securities for the three and six months ended June 30, 2016, respectively.

The following table presents the calculation of net earnings per common share (“EPS”) — basic and diluted (in thousands, except per share data):



	Three months ended June 30,					Six Months Ended June 30,
	2017			2016		2017		2016
Net (loss) income	$	(37,060	)	$	16,606	$	18,803	$	34,766
Weighted-average number of common shares outstanding (for basic calculation)	19,821			16,091		19,153		16,070
Dilutive securities	—			909		1,159		894
Weighted-average common and common equivalent shares outstanding (for diluted calculation)	19,821			17,000		20,312		16,964
EPS — basic	$	(1.87	)	$	1.03	$	0.98	$	2.16
EPS — diluted	$	(1.87	)	$	0.98	$	0.93	$	2.05

Derivative Financial Instruments (Notes)

6 Months Ended

Jun. 30, 2017

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Instruments and Hedging Activities Disclosure [Text Block]

Derivatives And Hedging Activities

Hedge Accounting and Hedging Program

During the second quarter of 2017, we implemented a cash flow hedging program. The purpose of our hedging program is to manage the foreign currency exchange rate risk on forecasted expenses denominated in currencies other than the functional currency of the operating unit. We do not issue derivatives for trading or speculative purposes.

In May 2017, we entered into a two-year cross-currency par forward contract to hedge a portion of our Mexico forecasted expenses denominated in Pesos ("MXN"). To receive hedge accounting treatment, all hedging relationships are formally documented at the inception of the hedge, and the hedges must be highly effective in offsetting changes to future cash flows on hedged transactions. The par forward contract is designated and qualifies as a cash flow hedge. Our derivative instrument is recorded at fair value on the Condensed Consolidated Balance Sheets and is classified based on the instrument's maturity date. We record changes in the intrinsic value of the effective portion of the gain or loss on the derivative instrument as a component of Other Comprehensive (Loss) Income and we reclassify that gain or loss into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings. Any gain or loss on the derivative instrument due to ineffectiveness of the hedge will be recognized in the Condensed Consolidated Statements of Operations during the current period. The total notional amount of our outstanding derivative as of June 30, 2017 was approximately 690.3 million MXN. The term of our currency forward contract is May 1, 2017 to May 1, 2019. The derivative instrument matures in equal monthly amounts at a fixed forward rate of 20.01MXN/USD over the term of the two-year contract.

The following table presents the fair values of our derivative instrument included within the Condensed Consolidated Balance Sheet as of June 30, 2017 and December 31, 2016 (in thousands):



	Asset Derivatives
	Condensed Consolidated Balance Sheet Location	June 30, 2017		December 31, 2016
Derivatives designated as cash flow hedging instruments
Foreign exchange forward contract:	Prepaid expenses and other current assets	$	941	$	—
	Other assets	863		—
Total derivatives designated as cash flow hedging instruments		$	1,804	$	—

The following table presents the amounts affecting the Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2017 and 2016 (in thousands):



	Line Item in the Condensed Consolidated Statements of Operations	Three Months Ended June 30,			Six Months Ended June 30,
		2017		2016	2017		2016
Derivatives designated as cash flow hedging instruments
Foreign exchange forward contracts	Cost of goods sold	$	22	—	$	22	—

We recognized the following gains on our foreign exchange contract designated as a cash flow hedge (in thousands):



	Amount of Gain Recognized in Other Comprehensive Income on Derivatives				Amount of Gain Reclassified From Accumulated Other Comprehensive Income into Income
	Three Months Ended					Three Months Ended
	June 30,					June 30,
	2017		2016		Location of Gain Reclassified From Accumulated Other Comprehensive Income into Income	2017		2016
Derivatives designated as cash flow hedges:
Foreign exchange forward contract	$	1,826	$	—	Cost of goods sold	$	22	$	—
Total derivatives designated as cash flow hedging instruments	$	1,826	$	—		$	22	$	—

As of June 30, 2017, we expect approximately $1.0 million of the deferred gains on the outstanding derivatives in accumulated other comprehensive income to be reclassified to net income during the next 12 months concurrent with the underlying hedged transactions also being reported in net income.



	Amount of Gain Recognized in Other Comprehensive Income on Derivatives				Amount of Gain Reclassified From Accumulated Other Comprehensive Income into Income
	Six Months Ended					Six Months Ended
	June 30,					June 30,
	2017		2016		Location of Gain Reclassified From Accumulated Other Comprehensive Income into Income	2017		2016
Derivatives designated as cash flow hedges:
Foreign exchange forward contract	$	1,826	$	—	Cost of goods sold	$	22	$	—
Total derivatives designated as cash flow hedging instruments	$	1,826	$	—		$	22	$	—

The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6441202&loc=d3e80720-113993

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624171-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64837297&loc=d3e41620-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624163-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5579240-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4D
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624177-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80784-113994

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=64837297&loc=d3e41641-113959

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5579245-113959

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4H
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624258-113959

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80748-113994

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5708775-113959

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5708773-113959

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5618551-113959

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5580258-113959

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4E
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624181-113959

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 25
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=64837297&loc=d3e41638-113959

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Fair Value Disclosures [Text Block]

Fair Value Measurement:

6 Months Ended

Jun. 30, 2017

Fair Value Disclosures [Abstract]

Fair Value Measurement

Fair value is the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. There are three levels of inputs that may be used to measure fair value:


•	Level 1: quoted prices in active markets for identical assets or liabilities;

•

Level 2: inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; or


•	Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair values of the assets or liabilities.

The fair value of our forward currency contract is estimated using observable market inputs such as known notional value amounts, spot and forward exchange rates. These inputs relate to liquid, heavily traded currencies with active markets which are available for the full term of the derivative.

During the first quarter of 2017, we recognized an earn-out liability upon the acquisition of HIS from Pfizer. Pfizer may be entitled up to $225 million in cash if certain performance targets for the combined company for the three years ending December 31, 2019 are achieved. The initial fair value of the earn-out was determined by employing a Monte Carlo simulation in a risk neutral framework. The underlying simulated variable was adjusted EBITDA. The adjusted EBITDA volatility estimate was based on a study of historical asset volatility for a set of comparable public companies. The model includes other assumptions including the market price of risk, which was calculated as the weighted average cost of capital ("WACC") less the long term risk free rate. At each reporting date subsequent to the acquisition we will remeasure the earn-out using the same methodology above and recognize any changes in value. If the probability of achieving the performance target significantly changes from what we initially anticipated, the change could have a significant impact on our financial statements in the period recognized. Our contingent earn-out liability is separately stated in our condensed consolidated balance sheets.

The following table provides a reconciliation of the Level 3 earn-out liability measured at estimated fair value based on an initial valuation and updated quarterly for the six months ended June 30, 2017 (in thousands):



	Earn-out Liability
Accrued balance, December 31, 2016	$	—
Acquisition date fair value estimate of earn-out	19,000
Change in fair value of earn-out (included in (loss) income from operations as a separate line item)	6,000
Accrued balance, June 30, 2017	$	25,000

The following table provides quantitative information about Level 3 inputs for fair value measurement of our earn-out liability as of the acquisition date and June 30, 2017. Significant increases or decreases in these inputs in isolation could result in a significant impact on our fair value measurement:



Simulation Input
Adjusted EBITDA Volatility	29.00	%
WACC	10.00	%
20-year risk free rate	2.82	%
Market price of risk	6.93	%
Cost of debt	4.16	%

The fair value of our long-term debt is estimated using discounted cash flows based on our incremental borrowing rate based on the London Interbank Offered Rate ("LIBOR"), which is a Level 2 input.

The assets related to our Dominican Republic manufacturing facilities are classified as assets held-for-sale. These assets are separately stated in our condensed consolidated balance sheet. The fair value of these assets was determined as part of the HIS business valuation and was based on estimated sales price less costs to sell.

There were no transfers between Levels during the three and six months ended June 30, 2017.

Our assets and liabilities measured at fair value on a recurring basis consisted of the following (Level 1, 2 and 3 inputs as defined above) (in thousands):



	Fair value measurements at June 30, 2017 using
	Total carrying value		Quoted prices in active markets for identical assets (level 1)		Significant other observable inputs (level 2)		Significant unobservable inputs (level 3)
Assets:
Foreign exchange forwards:
Prepaid expenses and other current assets	$	941	$	—	$	941	$	—
Other assets	863		$	—	863		$	—
Total Assets	$	1,804	$	—	$	1,804	$	—

Liabilities:
Earn-out liability	$	25,000	$	—	$	—	25,000
Senior note	75,000		—		75,000		—
Total Liabilities	$	100,000	$	—	$	75,000	$	25,000

Our assets measured at fair value on a nonrecurring basis consisted of the following (Level 1, 2 and 3 inputs as defined above) (in thousands):



	Fair value measurements at June 30, 2017 using
	Total carrying value		Quoted prices in active markets for identical assets (level 1)		Significant other observable inputs (level 2)		Significant unobservable inputs (level 3)
Assets:
Assets held-for-sale	$	2,508	$	—	$	—	2,508
Total Assets	$	2,508	$	—	$	—	$	2,508

Prepaid Expense and Other Assets, Current [Abstract]

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Prepaids and Other Current Assets (Notes)

6 Months Ended

Jun. 30, 2017

Other Current Assets [Text Block]

Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following (in thousands):



	June 30, 2017		December 31, 2016
Third-party receivables due from Pfizer	$	71,046	$	—
Prepaid and other expenses - HIS business acquisition related	31,084		—
Prepaid expenses - other	6,996		2,948
Prepaid insurance and property taxes	3,727		1,649
VAT/GST receivable	2,712		1,018
Other	5,793		1,740
	$	121,358	$	7,355

Third-party receivables due from Pfizer relates to trade accounts receivable that has already been collected from customers by Pfizer on our behalf.

Inventories:

6 Months Ended

Jun. 30, 2017

Inventory Disclosure [Abstract]

Inventories [Text Block]

Inventories

Inventories consisted of the following (in thousands):



	June 30, 2017		December 31, 2016
Raw material	$	83,440	$	28,435
Work in process	64,452		4,415
Finished goods	253,420		16,414
Total inventories	$	401,312	$	49,264

During the quarter ended March 31, 2017, we adopted ASU No. 2015-11, accordingly inventories are stated at lower of cost or net realizable value (see Note 2: New Accounting Pronouncements).

Property and Equipment:

6 Months Ended

Jun. 30, 2017

Property, Plant and Equipment [Abstract]

Property and Equipment [Text Block]

Property and Equipment

Property and equipment consisted of the following (in thousands):



	June 30, 2017			December 31, 2016
Machinery and equipment	$	222,658		$	96,536
Land, building and building improvements	202,634			63,524
Molds	51,214			39,014
Computer equipment and software	39,568			26,458
Furniture and fixtures	4,021			3,243
Construction in progress	36,861			15,180
Total property and equipment, cost	556,956			243,955
Accumulated depreciation	(182,366		)	(158,259		)
Property and equipment, net	$	374,590		$	85,696

Goodwill and Intangible Assets (Notes)

6 Months Ended

Jun. 30, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets Disclosure [Text Block]

Goodwill and Intangible Assets, Net

Goodwill

The following table presents the changes in the carrying amount of our goodwill for 2017 (in thousands):



	Total
Balance as of December 31, 2016	$	5,577
Goodwill acquired	1,015
Other	—
Currency translation	60
Balance as of June 30, 2017	$	6,652

The acquired goodwill relates to our February 1, 2017 acquisition of Fannin (see Note 3: Acquisitions and Strategic Transaction Expenses).

Intangible Assets, Net

Intangible assets, carried at cost less accumulated amortization and amortized on a straight-lined basis, were as follows (in thousands):



	Weighted Average	June 30, 2017
	Amortization Life in Years	Cost		Accumulated Amortization		Net
Patents	10	$	15,316	$	9,843	$	5,473
Customer contracts	9	9,533		4,702		4,831
Non-contractual customer relationships	9	63,080		3,743		59,337
Trademarks	4	425		425		—
Trade name	15	7,310		853		6,457
Developed technology	11	81,797		3,738		78,059
Total definite-lived intangible assets		$	177,461	$	23,304	$	154,157

Indefinite-lived IPR&D		6,189		—		6,189

Total intangible assets		$	183,650	$	23,304	$	160,346



	Weighted Average	December 31, 2016
	Amortization Life in Years	Cost		Accumulated Amortization		Net
Patents	10	$	14,423	$	9,326	$	5,097
MCDA contract *	10	8,571		8,571		—
Customer contracts	9	5,319		4,512		807
Non-contractual customer relationships	15	7,080		590		6,490
Trademarks	4	425		425		—
Trade name	15	7,310		609		6,701
Developed technology	10	3,797		509		3,288
Total		$	46,925	$	24,542	$	22,383

*MCDA contract: Manufacturing, Commercialization and Development Agreement with Hospira, Inc., dated May 1, 2005 (the "MCDA”). The MCDA was terminated in connection with the acquisition of the HIS business on February 3, 2017.

Intangible assets with definite lives are amortized on a straight-line basis over their estimated useful lives. During the three and six months ended June 30, 2017, intangible asset amortization expense was $3.9 million and $7.3 million, respectively, as compared to $0.7 million and $1.4 million during the three and six months ended June 30, 2016, respectively.

As of June 30, 2017 estimated annual amortization for our intangible assets for each of the next five years is approximately (in thousands):



Remainder of 2017	$	8,640
2018	17,156
2019	16,743
2020	16,604
2021	16,521
Thereafter	78,493
Total	$	154,157

Accounts Payable and Accrued Liabilities Disclosure [Text Block]

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Accrued Liabilities (Notes)

6 Months Ended

Jun. 30, 2017

Accrued Liabilities [Abstract]

Accrued Liabilities and Other Long-term Liabilities

Accrued liabilities consist of the following (in thousands):



	June 30, 2017		December 31, 2016
Salaries and benefits	$	54,674	$	5,702
Incentive compensation	17,487		7,912
Accrued product field action	14,151		—
Third-party inventory	13,078		—
Sales taxes	5,369		1,472
Restructuring accrual	4,905		423
Accrued insurance	3,857		—
Deferred revenue	3,697		18
Accrued professional fees	2,816		—
Legal accrual	2,585		4,177
Accrued marketing	2,125		—
Outside commissions	1,763		1,141
Warranties and returns	1,245		—
Acquisition-related accrual	—		2,750
Other	18,565		2,301
	$	146,317	$	25,896

Other long-term liabilities consist of the following (in thousands):



	June 30, 2017		December 31, 2016
Contract liabilities	$	56,948	$	—
Deferred revenue	5,678		—
Benefits	4,732		1,107
Product liability	3,122		—
Other	459		—
	$	70,939	$	1,107

Income Taxes:	6 Months Ended
Income Taxes:	Jun. 30, 2017
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	Income Taxes Income taxes were accrued at an estimated effective tax rate of (182)% and 28% for the six months ended June 30, 2017 and 2016, respectively. Those rates differ from that computed at the federal statutory rate of 35%. The effective tax rate for the six months ended June 30, 2017 differs from the federal statutory rate of 35% principally because of the effect the mix of U.S. and foreign incomes, state income taxes, tax credits and the impact of the gain on bargain purchase. The effective tax rate during the six months ended June 30, 2017 also included a material tax benefit of $9.9 million related to the excess tax benefits recognized on stock option exercises and the vesting of restricted stock units during the period. The income tax benefit was treated as a discrete item when determining the annual estimated effective tax rate. The effective tax rate for the six months ended June 30, 2016 differs from the federal statutory rate of 35% principally because of the effect of foreign and state income taxes, tax credits and deductions for domestic production activities. The effective tax rate during the six months ended June 30, 2016 also included a material tax benefit of $3.1 million related to the excess tax benefits recognized on stock option exercises and the vesting of restricted stock units during the period. The income tax benefit was treated as a discrete item when determining the annual estimated effective tax rate.

Long-Term Obligations (Notes)

6 Months Ended

Jun. 30, 2017

LOng-Term Obligations Disclosure [Abstract]

Long-term Debt [Text Block]

Long-Term Obligations

3-Year Interest-Only Senior Note

On February 3, 2017, we partially funded the acquisition of the HIS business from Pfizer with a $75 million Seller Note issued by Pfizer (the "Senior Note") contemporaneous with the acquisition. The Senior Note will mature on February 3, 2020.

Long-term obligations consisted of the following at June 30, 2017 (in thousands):



	June 30, 2017
Senior Note matures in 2020, variable interest rate	$	75,000
Less: current portion of long-term obligations	—
Long-term obligations, net	$	75,000

Principal payments

As of June 30, 2017, aggregate future principal payments for long-term obligations (including any current portion of long-term debt) were as follows (in thousands):



Years Ending
2017	$	—
2018	—
2019	—
2020	75,000
Thereafter	—
Total	$	75,000

The Senior Note is not subject to any required principal payments prior to the maturity date. We may, at our option, upon notice prepay without penalty at any time all, or from time to time any part of, this senior note at 100% of the principal amount, plus accrued but unpaid interest through the repayment date.

Interest rate

Interest on the Senior Note is variable and will accrue at LIBOR plus (i) 2.25% per year for the first 12 months, and (ii) 2.50% per annum thereafter. Interest is to be paid every three months following the February 3, 2017 effective date of the Senior Note.

Guarantors

Our obligations under the Senior Note are unconditionally guaranteed by each of our existing and subsequently acquired or formed wholly-owned domestic subsidiaries, subject to certain exclusions.

Debt Covenants

The Senior Note has restrictions, beginning on the effective date and thereafter, pertaining to limitations on debt, liens, loans, advances, acquisitions, other investments, dividends, redemptions, repurchases of equity interests, fundamental changes in the line of business, dispositions, transactions with affiliates, dividend and payment restrictions affecting subsidiaries, changes in line of business and accounting changes or change in fiscal year.

Stockholders' Equity (Notes)	6 Months Ended
Stockholders' Equity (Notes)	Jun. 30, 2017
Stockholders' Equity Attributable to Parent [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	Stockholders' Equity Common Stock On February 3, 2017, we acquired the HIS business from Pfizer and as partial consideration, we issued 3.2 million unregistered shares of our common stock to Pfizer. The fair value of the common stock was determined based on the closing price of our common shares on the issuance date, discounted to reflect a contractual lock-up period, whereby Pfizer is prohibited from the transfer of the shares, subject to certain exceptions, until the earlier of (i) the expiration of Pfizer’s services to us in the related transitional services agreement (see Note 17: Collaborative and Other Arrangements) or (ii) eighteen months. Treasury Stock In July 2010, our Board of Directors approved a common stock purchase plan to purchase up to $40.0 million of our common stock. This plan has no expiration date. During the three and six months ended June 30, 2017, we did not purchase any shares of our common stock under the stock purchase plan. As of June 30, 2017, the remaining authorized amount under this purchase plan is approximately $7.2 million. We are currently limited on share purchases in accordance with the terms and conditions of our Senior Note with Pfizer, (see Note 14: Long-Term Obligations). For the six months ended June 30, 2017, we withheld 25,864 shares of our common stock from employee vested restricted stock units in consideration for $3.7 million in payments made on the employee's behalf for their minimum statutory income tax withholding obligations. Treasury stock is used to issue shares for stock option exercises, restricted stock grants and employee stock purchase plan stock purchases.

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies:

6 Months Ended

Jun. 30, 2017

Commitments and Contingencies [Text Block]

Commitments and Contingencies

Legal Proceedings

Beginning in November 2016, purported class actions were filed in the U.S. District Court for the Northern District of Illinois against Pfizer subsidiaries, Hospira, Inc., Hospira Worldwide, Inc. and certain other defendants relating to the intravenous saline solutions part of the HIS business. Plaintiffs seek to represent classes consisting of all persons and entities in the U.S. who directly purchased intravenous saline solution sold by any of the defendants from January 1, 2013 until the time the defendants’ allegedly unlawful conduct ceases. Plaintiffs allege that the defendants’ conduct restricts output and artificially fixes, raises, maintains and/or stabilizes the prices of intravenous saline solution sold throughout the U.S. in violation of federal antitrust laws. Plaintiffs seek treble damages (for themselves and on behalf of the putative classes) and an injunction against defendants for alleged price overcharges for intravenous saline solution in the U.S. since January 1, 2013. On February 3, 2017, we completed the acquisition of the HIS business from Pfizer. This litigation is the subject of a claim for indemnification against us by Pfizer and a cross-claim for indemnification against Pfizer by us under the HIS Purchase Agreement.

In addition, in August 2015, the New York Attorney General issued a subpoena to Hospira, Inc. requesting that the company provide information regarding certain business practices in the intravenous solutions part of the HIS business. Separately, in April 2017, we received a grand jury subpoena issued by the United States District Court for the Eastern District of Pennsylvania, in connection with an investigation by the U.S. Department of Justice, Antitrust Division. The subpoena calls for production of documents related to the manufacturing, selling, pricing and shortages of intravenous solutions, including saline, as well as communications among market participants regarding these issues. The Department of Justice investigation is the subject of cross-claims for indemnification by both us and Pfizer under the HIS Purchase Agreement. We will coordinate with Pfizer to produce records to the New York Attorney General and the Department of Justice.

From time to time, we are involved in various legal proceedings, most of which are routine litigation, in the normal course of business. Our management does not believe that the resolution of the unsettled legal proceedings that we are involved with will have a material adverse impact on our financial position or results of operations.

Off Balance Sheet Arrangements

In the normal course of business, we have agreed to indemnify our officers and directors to the maximum extent permitted under Delaware law and to indemnify customers as to certain intellectual property matters or other matters related to sales of our products. There is no maximum limit on the indemnification that may be required under these agreements. Although we can provide no assurances, we have never incurred, nor do we expect to incur, any material liability for indemnification.

Contingencies

We have a contractual earn-out arrangement in connection with our acquisition of the HIS business, whereby Pfizer may be entitled up to an additional $225 million in cash upon achievement of performance targets for the company for the three years ending December 31, 2019, see (Note 3: Acquisitions and Strategic Transaction Expenses). The amount to be paid cannot be determined until the earn-out period has expired.

Commitments

As part of the HIS business acquisition, we assumed a number of non-cancellable operating office and industrial leases. Rental expense under operating lease agreements was $1.8 million and $3.0 million for the three and six months ended June 30, 2017, respectively, as compared to $0.1 million and $0.3 million for the three and six months ended June 30, 2016.

We also entered into the Senior Note with Pfizer to partially fund the HIS business acquisition (see Note 14: Long-Term Obligations).

The following table summarizes our principal contractual commitments, excluding open orders for purchases that support normal operations, as of June 30, 2017 (in thousands):



	Payments Due By Period
	Total		Remainder of 2017		2018		2019		2020		2021		Thereafter
Long-term debt obligations	$	75,000	$	—	$	—	$	—	$	75,000	$	—	$	—
Interest payments on long-term debt obligations	8,181		1,515		3,176		3,193		297		—		—
Operating lease obligations	34,258		4,300		8,284		5,591		3,316		3,216		9,551
Purchase obligations⁽¹⁾	101,854		9,397		4,477		14,005		34,757		39,218		—
Total contractual obligations	$	219,293	$	15,212	$	15,937	$	22,789	$	113,370	$	42,434	$	9,551

___________________________________

⁽¹⁾Purchase obligations includes agreements to purchase goods that are enforceable and legally binding. These amounts are not accrued as of June 30, 2017. We are committed to make potential future milestone payments to third parties under distribution agreements. Payments under these agreements are contingent upon achievement of certain developmental, regulatory and/or commercial milestones and are not included in the table above.

Collaborative and Other Arrangements (Notes)	6 Months Ended
Collaborative and Other Arrangements (Notes)	Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaborative Arrangement Disclosure [Text Block]	Collaborative and Other Arrangements On February 3, 2017, we entered into two Manufacturing and Supply Agreements ("MSA's"), (i) whereby Pfizer will manufacture and supply us with certain agreed upon products for an initial five-year term with a one-time two-year option to extend and (ii) whereby we will manufacture and supply Pfizer certain agreed upon products for a term of five or ten years depending on the product, also with a one-time two-year option to extend. The MSA's provide each party with mutually beneficial interests and both of the MSA's are to be jointly managed by both Pfizer and ICU. The initial supply price, which will be annually updated, is in full consideration for all costs associated with the manufacture, documentation, packaging and certification of the products. On February 3, 2017, as part of the HIS business acquisition, we entered into an agreement with Pfizer, whereby Pfizer will provide certain transitional services to us for finance, business technology, regulatory, human resources, global operations, procurement, quality and global commercial operation services ("Enabling Function Services"). We pay a monthly service fee for each service provided, and share equally with Pfizer in certain set-up costs and, as applicable, service exit costs. Our share of the set-up costs and service exit costs, in the aggregate, are not to exceed $22.0 million. The service fees are subject to a fee cap of (i) $62.5 million during the initial twelve month period and (ii) $31.3 million during the subsequent six month period. Only the Enabling Function Services are subject to the fee cap, any services provided after expiration of the agreement or services that are not Enabling Function Services may result in service fees outside the fee cap. The service fees are intended to reasonably approximate Pfizer’s cost of providing the Enabling Function Services. We may terminate, in whole only, any particular service and the fee cap would be reduced proportionate to the services terminated. Partial reduction in the provision of any specific service may be made but only with the prior written consent of Pfizer. On February 3, 2017, as part of the HIS business acquisition, we also entered into a reverse transitional services agreement, where we will provide to Pfizer certain transitional services ranging in term from three to eighteen months. Services include support for real estate, research and development, infrastructure, logistics, quality, site operations, safety, commercial and finance, and regulatory support services.

New Accounting Pronouncements New Accounting Pronouncements Adopted (Policies)	6 Months Ended
	Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Inventory, Policy [Policy Text Block]	Recently Adopted Accounting Standards In July 2015, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") No. 2015-11 Inventory (Topic 330): Simplifying the Measurement of Inventory. ASU 2015-11 changes the measurement of inventory within the scope of the ASU (e.g. FIFO or average cost) from lower of cost or market to lower of cost and net realizable value ("NRV"). NRV is defined as estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Prior to the ASU, U.S. generally accepted accounting principles required an entity to measure inventory at the lower of cost or market. Market is measured using replacement cost unless it is above NRV (commonly referred to as “ceiling”) or below NRV less an approximately normal profit margin (commonly referred to as “floor”). For inventory within its scope, the ASU eliminates the notions of replacement cost and NRV less a normal profit margin, which is intended to simplify the accounting for inventory. The amendments are effective prospectively for the fiscal years, and interim reporting periods within those years, beginning on or after December 15, 2016.

Restructuring Charges (Tables)

6 Months Ended

Jun. 30, 2017

Restructuring Charges [Abstract]

Restructuring and Related Costs [Table Text Block]

The following table summarizes the details of changes in our restructuring-related accrual for the period ending June 30, 2017 (in thousands):



	Accrued Balance December 31, 2016		Charges Incurred		Payments			Other Adjustments			Accrued Balance June 30, 2017
Severance pay and benefits	$	53	$	11,807	$	(7,313	)	$	(17	)	$	4,530
Employment agreement buyout	1,477		—		(183		)	—			1,294
Facility closure expenses	—		4,019		(2,067		)	(1,952		)	—
	$	1,530	$	15,826	$	(9,563	)	$	(1,969	)	$	5,824

Net Income Per Share (Tables)

6 Months Ended

Jun. 30, 2017

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

The following table presents the calculation of net earnings per common share (“EPS”) — basic and diluted (in thousands, except per share data):



	Three months ended June 30,					Six Months Ended June 30,
	2017			2016		2017		2016
Net (loss) income	$	(37,060	)	$	16,606	$	18,803	$	34,766
Weighted-average number of common shares outstanding (for basic calculation)	19,821			16,091		19,153		16,070
Dilutive securities	—			909		1,159		894
Weighted-average common and common equivalent shares outstanding (for diluted calculation)	19,821			17,000		20,312		16,964
EPS — basic	$	(1.87	)	$	1.03	$	0.98	$	2.16
EPS — diluted	$	(1.87	)	$	0.98	$	0.93	$	2.05

Derivative Financial Instruments (Tables)

6 Months Ended

Jun. 30, 2017

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Cash Flow Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]

The following table presents the fair values of our derivative instrument included within the Condensed Consolidated Balance Sheet as of June 30, 2017 and December 31, 2016 (in thousands):



	Asset Derivatives
	Condensed Consolidated Balance Sheet Location	June 30, 2017		December 31, 2016
Derivatives designated as cash flow hedging instruments
Foreign exchange forward contract:	Prepaid expenses and other current assets	$	941	$	—
	Other assets	863		—
Total derivatives designated as cash flow hedging instruments		$	1,804	$	—

The following table presents the amounts affecting the Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2017 and 2016 (in thousands):



	Line Item in the Condensed Consolidated Statements of Operations	Three Months Ended June 30,			Six Months Ended June 30,
		2017		2016	2017		2016
Derivatives designated as cash flow hedging instruments
Foreign exchange forward contracts	Cost of goods sold	$	22	—	$	22	—

Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]

We recognized the following gains on our foreign exchange contract designated as a cash flow hedge (in thousands):



	Amount of Gain Recognized in Other Comprehensive Income on Derivatives				Amount of Gain Reclassified From Accumulated Other Comprehensive Income into Income
	Three Months Ended					Three Months Ended
	June 30,					June 30,
	2017		2016		Location of Gain Reclassified From Accumulated Other Comprehensive Income into Income	2017		2016
Derivatives designated as cash flow hedges:
Foreign exchange forward contract	$	1,826	$	—	Cost of goods sold	$	22	$	—
Total derivatives designated as cash flow hedging instruments	$	1,826	$	—		$	22	$	—



	Amount of Gain Recognized in Other Comprehensive Income on Derivatives				Amount of Gain Reclassified From Accumulated Other Comprehensive Income into Income
	Six Months Ended					Six Months Ended
	June 30,					June 30,
	2017		2016		Location of Gain Reclassified From Accumulated Other Comprehensive Income into Income	2017		2016
Derivatives designated as cash flow hedges:
Foreign exchange forward contract	$	1,826	$	—	Cost of goods sold	$	22	$	—
Total derivatives designated as cash flow hedging instruments	$	1,826	$	—		$	22	$	—

Fair Value Measurement (Tables)

6 Months Ended

Jun. 30, 2017

Fair Value Disclosures [Abstract]

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]



	Earn-out Liability
Accrued balance, December 31, 2016	$	—
Acquisition date fair value estimate of earn-out	19,000
Change in fair value of earn-out (included in (loss) income from operations as a separate line item)	6,000
Accrued balance, June 30, 2017	$	25,000

Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block]



Simulation Input
Adjusted EBITDA Volatility	29.00	%
WACC	10.00	%
20-year risk free rate	2.82	%
Market price of risk	6.93	%
Cost of debt	4.16	%

Fair Value, Assets Measured on Recurring Basis [Table Text Block]

Our assets and liabilities measured at fair value on a recurring basis consisted of the following (Level 1, 2 and 3 inputs as defined above) (in thousands):



	Fair value measurements at June 30, 2017 using
	Total carrying value		Quoted prices in active markets for identical assets (level 1)		Significant other observable inputs (level 2)		Significant unobservable inputs (level 3)
Assets:
Foreign exchange forwards:
Prepaid expenses and other current assets	$	941	$	—	$	941	$	—
Other assets	863		$	—	863		$	—
Total Assets	$	1,804	$	—	$	1,804	$	—

Liabilities:
Earn-out liability	$	25,000	$	—	$	—	25,000
Senior note	75,000		—		75,000		—
Total Liabilities	$	100,000	$	—	$	75,000	$	25,000

Fair Value Measurements, Nonrecurring [Table Text Block]

Our assets measured at fair value on a nonrecurring basis consisted of the following (Level 1, 2 and 3 inputs as defined above) (in thousands):



	Fair value measurements at June 30, 2017 using
	Total carrying value		Quoted prices in active markets for identical assets (level 1)		Significant other observable inputs (level 2)		Significant unobservable inputs (level 3)
Assets:
Assets held-for-sale	$	2,508	$	—	$	—	2,508
Total Assets	$	2,508	$	—	$	—	$	2,508

Inventories (Tables)

6 Months Ended

Jun. 30, 2017

Inventory Disclosure [Abstract]

Schedule of Inventory, Current [Table Text Block]

Inventories consisted of the following (in thousands):



	June 30, 2017		December 31, 2016
Raw material	$	83,440	$	28,435
Work in process	64,452		4,415
Finished goods	253,420		16,414
Total inventories	$	401,312	$	49,264

Property and Equipment (Tables)

6 Months Ended

Jun. 30, 2017

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment [Table Text Block]

Property and equipment consisted of the following (in thousands):



	June 30, 2017			December 31, 2016
Machinery and equipment	$	222,658		$	96,536
Land, building and building improvements	202,634			63,524
Molds	51,214			39,014
Computer equipment and software	39,568			26,458
Furniture and fixtures	4,021			3,243
Construction in progress	36,861			15,180
Total property and equipment, cost	556,956			243,955
Accumulated depreciation	(182,366		)	(158,259		)
Property and equipment, net	$	374,590		$	85,696

Goodwill and Intangible Assets (Tables)

6 Months Ended

Jun. 30, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Goodwill [Table Text Block]

The following table presents the changes in the carrying amount of our goodwill for 2017 (in thousands):



	Total
Balance as of December 31, 2016	$	5,577
Goodwill acquired	1,015
Other	—
Currency translation	60
Balance as of June 30, 2017	$	6,652

Schedule of Intangible Assets and Goodwill [Table Text Block]

Intangible assets, carried at cost less accumulated amortization and amortized on a straight-lined basis, were as follows (in thousands):



	Weighted Average	June 30, 2017
	Amortization Life in Years	Cost		Accumulated Amortization		Net
Patents	10	$	15,316	$	9,843	$	5,473
Customer contracts	9	9,533		4,702		4,831
Non-contractual customer relationships	9	63,080		3,743		59,337
Trademarks	4	425		425		—
Trade name	15	7,310		853		6,457
Developed technology	11	81,797		3,738		78,059
Total definite-lived intangible assets		$	177,461	$	23,304	$	154,157

Indefinite-lived IPR&D		6,189		—		6,189

Total intangible assets		$	183,650	$	23,304	$	160,346



	Weighted Average	December 31, 2016
	Amortization Life in Years	Cost		Accumulated Amortization		Net
Patents	10	$	14,423	$	9,326	$	5,097
MCDA contract *	10	8,571		8,571		—
Customer contracts	9	5,319		4,512		807
Non-contractual customer relationships	15	7,080		590		6,490
Trademarks	4	425		425		—
Trade name	15	7,310		609		6,701
Developed technology	10	3,797		509		3,288
Total		$	46,925	$	24,542	$	22,383

Accrued Liabilities (Tables)

6 Months Ended

Jun. 30, 2017

Accrued Liabilities [Abstract]

Schedule of Accrued Liabilities [Table Text Block]

Accrued liabilities consist of the following (in thousands):



	June 30, 2017		December 31, 2016
Salaries and benefits	$	54,674	$	5,702
Incentive compensation	17,487		7,912
Accrued product field action	14,151		—
Third-party inventory	13,078		—
Sales taxes	5,369		1,472
Restructuring accrual	4,905		423
Accrued insurance	3,857		—
Deferred revenue	3,697		18
Accrued professional fees	2,816		—
Legal accrual	2,585		4,177
Accrued marketing	2,125		—
Outside commissions	1,763		1,141
Warranties and returns	1,245		—
Acquisition-related accrual	—		2,750
Other	18,565		2,301
	$	146,317	$	25,896

Other long-term liabilities consist of the following (in thousands):



	June 30, 2017		December 31, 2016
Contract liabilities	$	56,948	$	—
Deferred revenue	5,678		—
Benefits	4,732		1,107
Product liability	3,122		—
Other	459		—
	$	70,939	$	1,107

Long-Term Obligations (Tables)

6 Months Ended

Jun. 30, 2017

Debt Instrument [Line Items]

Schedule of Long-term Debt Instruments [Table Text Block]

Long-term obligations consisted of the following at June 30, 2017 (in thousands):



	June 30, 2017
Senior Note matures in 2020, variable interest rate	$	75,000
Less: current portion of long-term obligations	—
Long-term obligations, net	$	75,000

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28541-108399

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

LOng-Term Obligations Disclosure [Abstract]

Long-Term Obligations Principal Payments (Tables)

6 Months Ended

Jun. 30, 2017

Schedule of Maturities of Long-term Debt [Table Text Block]

Principal payments

As of June 30, 2017, aggregate future principal payments for long-term obligations (including any current portion of long-term debt) were as follows (in thousands):



Years Ending
2017	$	—
2018	—
2019	—
2020	75,000
Thereafter	—
Total	$	75,000

Commitments and Contingencies Commitments and Contingencies (Tables)

6 Months Ended

Jun. 30, 2017

Commitments and Contingencies Disclosure [Abstract]

Contractual Obligation, Fiscal Year Maturity Schedule [Table Text Block]

The following table summarizes our principal contractual commitments, excluding open orders for purchases that support normal operations, as of June 30, 2017 (in thousands):



	Payments Due By Period
	Total		Remainder of 2017		2018		2019		2020		2021		Thereafter
Long-term debt obligations	$	75,000	$	—	$	—	$	—	$	75,000	$	—	$	—
Interest payments on long-term debt obligations	8,181		1,515		3,176		3,193		297		—		—
Operating lease obligations	34,258		4,300		8,284		5,591		3,316		3,216		9,551
Purchase obligations⁽¹⁾	101,854		9,397		4,477		14,005		34,757		39,218		—
Total contractual obligations	$	219,293	$	15,212	$	15,937	$	22,789	$	113,370	$	42,434	$	9,551

___________________________________

Acquisition and Strategic Transaction Text Details - USD ($) shares in Thousands, $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2017	Jun. 30, 2016
Business Acquisition [Line Items]
Payments to Acquire Businesses, Gross	$ 260,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	139,000	$ 139,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets	$ 5,000	5,000
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	9 years
Business Combination, Consideration Transferred	$ 684,666
Fair value of Seller Note	75,000	$ 75,000	$ 0
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares		3,200
contingent consideration gross	225,000
Earn out Target	1,000,000	$ 1,000,000
Series of Individually Immaterial Business Acquisitions [Member]
Business Acquisition [Line Items]
Payments to Acquire Businesses, Gross	1,500
Customer Relationships [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	$ 56,000	56,000
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	8 years
Pumps and dedicated sets [Domain] \| Developed Technology Rights [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	$ 44,000	44,000
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	10 years
Consumables [Domain] \| Developed Technology Rights [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	$ 34,000	$ 34,000
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	12 years

Acquisition and Strategic Transaction Details - Transaction Expenses - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Business Combinations [Abstract]
Strategic Transaction Costs		$ 1.1
Strategic transaction expenses	$ 12.4		$ 33.5	$ 1.1

Acquisition and Strategic Transaction Purchase Price Allocation Table (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Business Combinations [Abstract]
Payments to Acquire Businesses, Gross	$ 177,527
Fair value of seller note	75,000		$ 75,000	$ 0
Business Combination, Contingent Consideration, Liability, Noncurrent	$ 19,000		$ 19,000		$ 0
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares			3,200
Business Acquisition, Share Price	$ 140.75		$ 140.75
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable	$ 450,400
Discount on equity issued as consideration	(37,261)
Business Combination, Consideration Transferred, Equity Issued, Fair Value	413,139		$ 413,139	0
Business Combination, Consideration Transferred	684,666
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents	29,475		29,475
Business Combination, Acquired Receivables, Fair Value	362		362
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory	417,317		417,317
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets	4,766		4,766
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment	288,486		288,486
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	139,000		139,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent	(27,101)		(27,101)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other	31,283		31,283
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable	(12,381)		(12,381)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other	(54,794)		(54,794)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities	(68,510)		(68,510)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net	775,004		775,004
BARGAIN PURCHASE GAIN	$ 0	$ (1,110)	$ (63,237)	$ (1,110)

Restructuring Charges Restructuring Table $ in Thousands	6 Months Ended
Restructuring Charges Restructuring Table $ in Thousands	Jun. 30, 2017 USD ($)
Restructuring Reserve [Roll Forward]
Restructuring Reserve	$ 1,530
Restructuring Charges	15,826
Payments for Restructuring	(9,563)
Restructuring Reserve, Accrual Adjustment	(1,969)
Restructuring Reserve	5,824
Employee Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve	53
Restructuring Charges	11,807
Payments for Restructuring	(7,313)
Restructuring Reserve, Accrual Adjustment	(17)
Restructuring Reserve	4,530
Special Termination Benefits [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve	1,477
Restructuring Charges	0
Payments for Restructuring	(183)
Restructuring Reserve, Accrual Adjustment	0
Restructuring Reserve	1,294
Facility Closing [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve	0
Restructuring Charges	4,019
Payments for Restructuring	(2,067)
Restructuring Reserve, Accrual Adjustment	(1,952)
Restructuring Reserve	$ 0

Net Income Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Net income	$ (37,060)	$ 16,606	$ 18,803	$ 34,766
Weighted average number of common shares outstanding (for basic calculation)	19,821	16,091	19,153	16,070
Dilutive securities	0	909	1,159	894
Diluted (in shares)	19,821	17,000	20,312	16,964
EPS - basic	$ (1.87)	$ 1.03	$ 0.98	$ 2.16
Diluted (In dollars per share)	$ (1.87)	$ 0.98	$ 0.93	$ 2.05

Net Income Per Share (Details 1) - shares	3 Months Ended
Net Income Per Share (Details 1) - shares	Jun. 30, 2017	Jun. 30, 2016
Earnings Per Share [Abstract]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6,239	0

Derivative Financial Instruments (Details) $ in Millions	Jun. 30, 2017 USD ($)
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months	$ 1.0
Derivative, Notional Amount	$ 690.3
Derivative, Forward Exchange Rate	20.01

Derivative Financial Instruments Derivative Instruments and Hedging Activities - FV of Derivative Instruments Included Within Consolidated Balance Sheet (Details) - Foreign Exchange Forward [Member] - Designated as Hedging Instrument [Member] - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Prepaid Expenses and Other Current Assets [Member]
Derivatives, Fair Value [Line Items]
Derivative Asset	$ 941	$ 0
Other Assets [Member]
Derivatives, Fair Value [Line Items]
Derivative Asset	863	0
Derivative Financial Instruments, Assets [Member]
Derivatives, Fair Value [Line Items]
Derivative Asset	$ 1,804	$ 0

Derivative Financial Instruments Derivative Instruments and Hedging Activities - Amounts Affecting Consolidated Statements of Income (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Gain (Loss) on Derivative, Net	$ 22	$ 0	$ 22	$ 0

Derivative Financial Instruments Derivative Instruments and Hedging Activities - Cash Flow Hedge Activity Included in Accumulated Other Comprehensive Income (Loss) (Details) - Cost of Sales [Member] - Foreign Exchange Forward [Member] - Cash Flow Hedging [Member] - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative Instruments, Gain Recognized in Other Comprehensive Income (Loss), Effective Portion	$ 1,826	$ 0	$ 1,826	$ 0
Derivative Instruments, Gain Reclassified from Accumulated OCI into Income, Effective Portion	$ 22	$ 0	$ 22	$ 0

Fair Value Measurement Fair Value Measurement (Details) $ in Millions	3 Months Ended
	Jun. 30, 2017 USD ($)
Fair Value Disclosures [Abstract]
contingent consideration gross	$ 225

Fair Value Measurement Fair Value Liabilities Measured on Recurring Basis, Unobservable Inputs (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Fair Value Disclosures [Abstract]
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value	$ 25,000	$ 0
Fair Value, Liabilities Measured on Recurring Basis, Change in Unrealized Gain (Loss)	6,000
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances	$ 19,000

Fair Value Measurement Fair Value Inputs, Liabilities, Quantitative Information (Details)	6 Months Ended
	Jun. 30, 2017
Fair Value Disclosures [Abstract]
Adjusted EBITDA Volatility	29.00%
WACC	10.00%
20-year risk free rate	2.82%
Market price of risk	6.93%
Cost of debt	4.16%

Fair Value Measurement Fair value nonrecurring basis (Details) $ in Thousands	Jun. 30, 2017 USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets Held-for-sale, Long Lived, Fair Value Disclosure	$ 2,508
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets Held-for-sale, Long Lived, Fair Value Disclosure	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets Held-for-sale, Long Lived, Fair Value Disclosure	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets Held-for-sale, Long Lived, Fair Value Disclosure	$ 2,508

Prepaids and Other Current Assets (Details) - USD ($)
$ in Thousands

Jun. 30, 2017

Dec. 31, 2016

Prepaid Expense and Other Assets, Current [Abstract]

Other Receivables

$ 71,046

$ 0

Prepaids - HIS transaction

31,084

Other Prepaid Expense, Current

6,996

2,948

Prepaid insurance and property taxes

3,727

1,649

Prepaid Taxes

2,712

1,018

Other Assets, Current

5,793

1,740

Prepaid expenses and other current assets

$ 121,358

$ 7,355

^[1]

[1]	December 31, 2016 balances were derived from audited consolidated financial statements.

Inventories (Details) - USD ($)
$ in Thousands

Jun. 30, 2017

Dec. 31, 2016

Inventory Disclosure [Abstract]

Raw material

$ 83,440

$ 28,435

Work in process

64,452

4,415

Finished goods

253,420

16,414

Total

$ 401,312

$ 49,264

^[1]

[1]	December 31, 2016 balances were derived from audited consolidated financial statements.

Property and Equipment (Details) - USD ($)
$ in Thousands

Jun. 30, 2017

Dec. 31, 2016

Net property and equipment

$ 556,956

$ 243,955

Accumulated depreciation

(182,366)

(158,259)

374,590

85,696

^[1]

Machinery and Equipment, Gross

222,658

96,536

Furniture and Fixtures, Gross

4,021

3,243

Construction in Progress, Gross

36,861

15,180

Land, Buildings and Improvements [Member]

202,634

63,524

Molds [Member]

Computer Equipment and Software [Member]

51,214

39,014

Goodwill, Acquired During Period

$ 39,568

$ 26,458

[1]	December 31, 2016 balances were derived from audited consolidated financial statements.

Goodwill and Intangible Assets Goodwill Table - USD ($)
$ in Thousands

3 Months Ended

6 Months Ended

Jun. 30, 2017

Dec. 31, 2016

^[1]

Goodwill [Line Items]

GOODWILL

$ 6,652

$ 5,577

1,015

$ 1,015

Goodwill, Purchase Accounting Adjustments

Goodwill, Foreign Currency Translation Gain (Loss)

$ 60

[1]	December 31, 2016 balances were derived from audited consolidated financial statements.

Goodwill and Intangible Assets Intangibles Table (Details) - USD ($)
$ in Thousands

3 Months Ended

12 Months Ended

Jun. 30, 2017

Dec. 31, 2016

Finite-Lived Intangible Assets, Accumulated Amortization

$ 177,461

$ 46,925

23,304

24,542

Indefinite-Lived Intangible Assets (Excluding Goodwill)

154,157

22,383

6,189

Intangible Assets, Gross (Excluding Goodwill)

183,650

INTANGIBLE ASSETS, net

$ 160,346

$ 22,383

^[1]

Patents [Member]

10 years

Finite-Lived Intangible Assets, Accumulated Amortization

$ 15,316

$ 14,423

9,843

9,326

$ 5,473

$ 5,097

MCDA contract [Member]

10 years

Finite-Lived Intangible Assets, Accumulated Amortization

$ 8,571

8,571

Customer Contracts [Member]

$ 0

9 years

Finite-Lived Intangible Assets, Accumulated Amortization

$ 9,533

$ 5,319

4,702

4,512

$ 4,831

$ 807

9 years

15 years

Finite-Lived Intangible Assets, Accumulated Amortization

$ 63,080

$ 7,080

3,743

590

$ 59,337

$ 6,490

Trademarks [Member]

4 years

Finite-Lived Intangible Assets, Accumulated Amortization

$ 425

425

$ 0

Trade Names [Member]

15 years

Finite-Lived Intangible Assets, Accumulated Amortization

$ 7,310

853

609

Developed Technology Rights [Member]

$ 6,457

$ 6,701

11 years

10 years

Finite-Lived Intangible Assets, Accumulated Amortization

$ 81,797

$ 3,797

3,738

509

Accrued product field action

$ 78,059

$ 3,288

[1]	December 31, 2016 balances were derived from audited consolidated financial statements.

Goodwill and Intangible Assets Text (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of Intangible Assets	$ 3.9	$ 0.7	$ 7.3	$ 1.4

Goodwill and Intangible Assets 5-Year Amortization (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	$ 8,640
Finite-Lived Intangible Assets, Amortization Expense, Year Two	17,156
Finite-Lived Intangible Assets, Amortization Expense, Year Three	16,743
Finite-Lived Intangible Assets, Amortization Expense, Year Four	16,604
Finite-Lived Intangible Assets, Amortization Expense, Year Five	16,521
Finite-Lived Intangible Assets, Amortization Expense, after Year Five	78,493
Finite-Lived Intangible Assets, Net	$ 154,157	$ 22,383

Accrued Liabilities (Details) - USD ($)
$ in Thousands

3 Months Ended

6 Months Ended

Jun. 30, 2017

Jun. 30, 2016

Dec. 31, 2016

Accrued Liabilities [Abstract]

Salaries and benefits

$ 54,674

$ 5,702

Incentive compensation

17,487

7,912

14,151

Third-party Inventory

13,078

$ 0

Sales taxes

5,369

1,472

Restructuring accrual

4,905

423

Accrued insurance

3,857

Deferred revenue

3,697

Accrued Professional Fees

2,816

Legal accrual

2,585

4,177

Accrued marketing

2,125

Outside commissions

1,763

1,141

Warranties and returns

1,245

Acquisition-related accrual

2,750

Other

18,565

2,301